JP2024506020A5 - - Google Patents

Info

Publication number
JP2024506020A5
JP2024506020A5 JP2023547452A JP2023547452A JP2024506020A5 JP 2024506020 A5 JP2024506020 A5 JP 2024506020A5 JP 2023547452 A JP2023547452 A JP 2023547452A JP 2023547452 A JP2023547452 A JP 2023547452A JP 2024506020 A5 JP2024506020 A5 JP 2024506020A5
Authority
JP
Japan
Prior art keywords
salvecovirus
seq
nos
conjugate
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506020A (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/052885 external-priority patent/WO2021156490A2/en
Application filed filed Critical
Priority claimed from PCT/EP2022/052919 external-priority patent/WO2022167666A1/en
Publication of JP2024506020A publication Critical patent/JP2024506020A/ja
Publication of JP2024506020A5 publication Critical patent/JP2024506020A5/ja
Pending legal-status Critical Current

Links

JP2023547452A 2021-02-05 2022-02-07 サルベコウイルス結合剤 Pending JP2024506020A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/052885 2021-02-05
PCT/EP2021/052885 WO2021156490A2 (en) 2020-02-06 2021-02-05 Corona virus binders
EP21166835 2021-04-02
EP21166835.5 2021-04-02
EP21173680.6 2021-05-12
EP21173680 2021-05-12
PCT/EP2022/052919 WO2022167666A1 (en) 2021-02-05 2022-02-07 Sarbecovirus binders

Publications (2)

Publication Number Publication Date
JP2024506020A JP2024506020A (ja) 2024-02-08
JP2024506020A5 true JP2024506020A5 (https=) 2025-02-13

Family

ID=80625002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547452A Pending JP2024506020A (ja) 2021-02-05 2022-02-07 サルベコウイルス結合剤

Country Status (8)

Country Link
US (1) US20240101647A1 (https=)
EP (1) EP4288095A1 (https=)
JP (1) JP2024506020A (https=)
KR (1) KR20230141853A (https=)
AU (1) AU2022216460A1 (https=)
CA (1) CA3207548A1 (https=)
IL (1) IL304929A (https=)
WO (1) WO2022167666A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117794566A (zh) * 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
IT202200025416A1 (it) * 2022-12-13 2024-06-13 Univ Pisa Biosensore per la rilevazione di particelle virali
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
WO2001040310A2 (en) 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン.ヴェー. 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4707303A2 (en) 2014-05-16 2026-03-11 Ablynx NV Improved immunoglobulin variable domains

Similar Documents

Publication Publication Date Title
JP2024506020A5 (https=)
JP2023516280A5 (https=)
JP2016529882A5 (https=)
US11993655B2 (en) Anti-PD-L1 antibody and use thereof
AU2016334290B2 (en) Antibody to hepatitis B surface antigen and use thereof
JP2012504955A5 (https=)
JP2018514193A5 (https=)
US20240207401A1 (en) Coronavirus antibody
KR101682040B1 (ko) Msrv 관련 질환에서 특이적 리간드의 치료적 용도
JP2018522540A5 (https=)
EP3351265A1 (en) Anti-herv-k envelope antibody and uses thereof
JP2023542107A (ja) SARS-CoV-2を標的とするシングルドメイン抗体
JP2022512647A5 (https=)
JP2023534922A (ja) SARS-CoV-2を標的とする抗原結合分子
CA2637152A1 (en) Antigen-binding proteins targeting s. aureus orf0657n
JP2026510999A (ja) Cd19/cd38多重特異性抗体
JP2019514343A5 (https=)
CN111978393B (zh) 抗乙肝病毒新型抗体及其用途
JP2024500322A (ja) 併用療法
JP2024543134A5 (https=)
CN115975020A (zh) 靶向sars-cov-2s蛋白的抗原结合蛋白及其应用
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
US12054556B2 (en) Anti-PD-L1 antibody and use thereof
RU2814471C2 (ru) Новые антитела против вируса гепатита b и их применение
WO2024196463A2 (en) Broadly neutralizing human monoclonal antibodies that target the sars-cov-2 receptor binding domain (rbd)